EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late‐stage incidence end points and post‐trial ongoing evaluation—The Peachtree Consensus

Ruth Etzioni iD, Larry Kessler iD, Deb Schrag iD, Peter Sasieni iD, Hilary A Robbins iD, Hormuzd A Katki iD, Stephen W Duffy iD, Roman Gulati iD, Diana Buist iD, Sean Tunis iD, Rebecca Landy iD, Jane Lange iD und 3 weitere

Cancer · 01.10.2026 · 132 (19)

DOI: 10.1002/cncr.70628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 23.09.2026. Verfasst von Ruth Etzioni und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Neoplasms, Early Detection of Cancer, Research Design, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a new era of multicancer early detection (MCED), late‐stage incidence has been proposed as an end point for the evaluation of test efficacy, marking a departure from the established end point of cancer mortality.

Methods

The American Cancer Society convened a panel of 15 academic researchers with expertise in cancer screening evaluation to develop principles assuring the validity and interpretability of MCED trials with late‐stage incidence end points and advancing implementation of tests with potential for meaningful clinical utility.

Results

The definition of late‐stage cancer is critical and affects study design, interpretation, and outcomes. The authors of the Peachtree Consensus recommend considering cancer‐type–specific definitions of late stage and paying attention to comparability of staging intensity in both trial arms. The duration of screening and the follow‐up interval after the last screen should be chosen based on the preclinical early stage and late‐stage durations of the target cancer types. The authors also recommend reporting aggregate results and results for individual cancer types as numbers permit and summarizing relative and absolute benefits. Predicted mortality reductions should be calculated to contextualize a late‐stage result and the inputs and assumptions involved should be reported. Given a significant late‐stage reduction suggestive of meaningful clinical benefit, the authors support launching consortium and demonstration studies while continuing to track trial mortality outcomes.

Conclusions

Trials with late‐stage incidence end points that are conducted using these principles should support the development of evidence‐based screening guidelines as well as the creation of accessible data resources for observational and modeling studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsEarly Detection of CancerResearch DesignClinical Trials as TopicHumansAmerican Cancer SocietyUnited StatesIncidence

Stichwörter der Autor:innen

cancer screeninglate‐stage incidencemulticancer early detectionrandomized trialssurrogate end points

Autor:innen und Institutionen

  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Centre for Cancer Screening, Prevention, and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Early Detection, Prevention, and Infections Branch, International Agency for Research on Cancer, Lyon, France.
  • Center for Early Cancer Detection, American Cancer Society, Atlanta, Georgia, USA.

ORCID-Profile: Ruth Etzioni, Larry Kessler, Deb Schrag, Peter Sasieni, Hilary A Robbins, Hormuzd A Katki, Stephen W Duffy, Roman Gulati, Diana Buist, Sean Tunis, Rebecca Landy, Jane Lange, Alpa V Patel, William L Dahut, Robert A Smith

Förderung

  • NCI NIH HHS
  • American Cancer Society

Zitieren

APA

Etzioni, R., Kessler, L., Schrag, D., Sasieni, P., Robbins, H. A., Katki, H. A., Duffy, S. W., Gulati, R., Buist, D., Tunis, S., Landy, R., Lange, J., Patel, A. V., Dahut, W. L., & Smith, R. A. (2026). Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late‐stage incidence end points and post‐trial ongoing evaluation—The Peachtree Consensus. Cancer, 132(19). https://doi.org/10.1002/cncr.70628

Vancouver

Etzioni R, Kessler L, Schrag D, Sasieni P, Robbins HA, Katki HA, et al. Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late‐stage incidence end points and post‐trial ongoing evaluation—The Peachtree Consensus. Cancer. 2026;132(19). doi:10.1002/cncr.70628

BibTeX
@article{Etzioni2026,
  author = {Etzioni, Ruth and Kessler, Larry and Schrag, Deb and Sasieni, Peter and Robbins, Hilary A and Katki, Hormuzd A and Duffy, Stephen W and Gulati, Roman and Buist, Diana and Tunis, Sean and Landy, Rebecca and Lange, Jane and Patel, Alpa V and Dahut, William L and Smith, Robert A},
  title = {Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late‐stage incidence end points and post‐trial ongoing evaluation—The Peachtree Consensus},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {19},
  doi = {10.1002/cncr.70628}
}
Kostenlos starten →